Elevated Platelet Count is Associated with Poor Survival After Transarterial Chemoembolization Treatment in Patients with Hepatocellular Carcinoma: A Cohort Study
Received 30 July 2020
Accepted for publication 17 September 2020
Published 15 October 2020 Volume 2020:7 Pages 191—199
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Ahmed Kaseb
linbin Lu,1,* Yan Zhang,1,* Peichan Zheng,2,* Zhixian Wu,3 Xuewen Wang,1 Yaying Chen,1 Xiong Chen1
1Department of Oncology, The 900th Hospital of Joint Logistic Support Force, PLA, Fuzong Clinical College of Fujian Medical University, Fuzhou, Fujian 350025, People’s Republic of China; 2Fujian Center for Safety Evaluation of New Drug, Fujian Medical University, Fuzhou, Fujian 350122, People’s Republic of China; 3Department of Hepatobiliary, The 900th Hospital of Joint Logistic Support Force, PLA, Fuzong Clinical College of Fujian Medical University, Fuzhou, Fujian 350025, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xiong Chen
Department of Oncology, The 900th Hospital of Joint Logistic Support Force, PLA, Fuzong Clinical College of Fujian Medical University, 156 Xierhuan Northern Road, Fuzhou, Fujian 350025, People’s Republic of China
Tel +86 1-216-612-2438
Background: Platelet count (PLT) has been proved as an essential biomarker for the survival of hepatocellular carcinoma (HCC). However, the prognostic value of PLT change (ΔPLT) is still uncertain. The aim of this study was to explore the relationship between ΔPLT and HCC survival after transarterial chemoembolization (TACE) treatment.
Methods: Cox proportional hazard regression models were used to calculate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for HCC. The non-linear relationship between ΔPLT and OS was estimated through a restricted cubic spline regression analysis, and a two-piece-wise Cox proportional hazard model was further performed to calculate the threshold effect.
Results: A total of 597 HCC patients treated with TACE were selected for the secondary analysis. Compared with the ΔPLT within ± 20 (× 109/L), ΔPLT≥ 20 (× 109/L) was significantly associated with an 64% increase in risk of death (HR, 1.64; 95% CI: 1.21 to 2.22) after adjustment for confounding variables, but the association was not significant in the group of ΔPLT≤-20 (HR, 1.23; 95% CI: 0.92 to 1.63). We also found a U-shape relationship between ΔPLT and HCC survival at the turning point of ΔPLT as 0 (20× 109/L). The HR for the death was 1.12 (95% CI: 1.06, 1.18) with ΔPLT≥ 0 (20× 109/L) while 0.95 (95% CI: 0.92, 0.98) with ΔPLT< 0 (20× 109/L). After potential confounding factors were adjusted, the non-linear relationship between ΔPLT and OS was still significant (P=0.013). Besides, ΔPLT≥ 20 (× 109/L) was associated with new lesions (OR, 2.74; 95% CI: 1.38 to 5.45).
Conclusion: Elevated PLT was associated with poor overall survival of HCC patients after TACE treatment.
Keywords: hepatocellular carcinoma, transarterial chemoembolization, platelet count, prognosis, real-world study
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]